• Publications
  • Influence
Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung
PURPOSE To evaluate the efficacy of cetuximab added to first-line gemcitabine/platinum in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS In thisExpand
  • 76
  • 8
Multiple transport pathways for neutral amino acids in rabbit jejunal brush border vesicles
SummaryAmino acids enter rabbit jejunal brush border membrane vesicles via three major transport systems: (1) simple passive diffusion; (2) Na-independent carriers; and (3) Na-dependent carriers. TheExpand
  • 97
  • 7
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer
Purpose To evaluate the efficacy of cetuximab added to first-line gemcitabine/platinum in chemotherapy-naive patients with advanced non–small-cell lung cancer (NSCLC). Patients and Methods In thisExpand
  • 179
  • 6
Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim
A significant variation in susceptibility to paclitaxel-mediated killing was observed among a panel of short-term cultured non-small-cell lung cancer (NSCLC) cell lines. Susceptibility to killing byExpand
  • 119
  • 5
Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve
Introduction: Performance status (PS) 2 patients with non-small cell lung cancer (NSCLC) experience more toxicity, lower response rates, and shorter survival times than healthier patients treatedExpand
  • 161
  • 4
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
BACKGROUND To date, few large studies have been reported of patients with peritoneal mesothelioma, and treatment of this disease has been largely extrapolated from the treatment of pleural disease.Expand
  • 138
  • 4
Cytokine messenger RNA stability is enhanced in tumor cells.
Hematopoietic growth factors are produced by a number of human tumors. We extracted RNA from selected human tumor cells known to produce at least one hematopoietic growth factor and found high levelsExpand
  • 66
  • 4
  • PDF
Expert Consensus Document on Pulmonary Metastasectomy.
Thoracic Surgery, Providence Health & Services, Portland, Oregon; Norton Thoracic Institute, St. Joseph’s Hospital andMedical Center, Phoenix, Arizona; Medical Oncology, Providence Cancer Center,Expand
  • 27
  • 4
  • PDF
A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528
Introduction: The purpose of this study was to assess the safety and efficacy of gemcitabine and carboplatin with (arm A) or without (arm B) daily oral cediranib as first-line therapy for advancedExpand
  • 31
  • 3
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX‐710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer
Tumors with multidrug resistance (MDR) frequently up‐regulate efflux proteins, including MDR‐associated protein (MRP‐1) and P‐glycoprotein (Pgp). MDR represents an obstacle to successful chemotherapyExpand
  • 64
  • 2